Dashboard
Vertex Pharmaceuticals Incorporated
VRTXNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 19Trial initiationClinicalTrials.gov
Phase 3b trial NCT07890909 of Povetacicept autoinjector vs Sibeprenlimab syringe begins recruiting.
- Nov 18Ownership changeSEC
Form 4 insider transaction filing dated 2026-11-18.
- Nov 18Trial initiationClinicalTrials.gov
Vertex initiates Phase 2/3 trial of povetacicept in primary membranous nephropathy (NCT07204275, recruiting).
- Nov 18Ownership changeSEC
Form 4 insider transaction filing for Vertex Pharmaceuticals.
- Nov 17Trial readoutClinicalTrials.gov
Vertex completes Phase 4 single-arm trial NCT06887959 of Suzetrigine for acute post-surgical pain.
- Nov 17Trial initiationClinicalTrials.gov
Vertex Phase 3b trial NCT07890909 of Povetacicept autoinjector vs Sibeprenlimab syringe now recruiting
- Nov 17Trial readoutClinicalTrials.gov
Vertex updates NCT06696443 Phase 3 long-term safety/efficacy trial of suzetrigine in painful DPN; status ACTIVE_NOT_RECRUITING as of 2026-11-17.
- Nov 16Trial readoutClinicalTrials.gov
Completed Phase 4 single-arm study NCT06887972 of suzetrigine for acute post-surgical pain
- Nov 16Ownership changeSEC
Form 4 insider transaction filing for Vertex Pharmaceuticals.
- Nov 12Trial readoutClinicalTrials.gov
Vertex completes Phase 4 trial NCT07538570 evaluating pain treatment after total knee arthroplasty.
- Nov 12Trial readoutClinicalTrials.gov
Vertex updates ClinicalTrials.gov NCT06747572 (PKD1 gene variants in ADPKD); status ACTIVE_NOT_RECRUITING, phase N/A, sponsor Vertex.
- Nov 10Ownership changeSEC
SEC Form 4 insider transaction filing for Vertex Pharmaceuticals.
- Nov 2Financial resultsSEC
Vertex Pharmaceuticals 8-K (items 2.02, 9.01) reports results of operations.
- Oct 30OtherClinicalTrials.gov
Phase 3 trial NCT06696443 for long-term safety/effectiveness of suzetrigine in painful diabetic peripheral neuropathy updated to active, not recruiting.
- Oct 30Trial initiationClinicalTrials.gov
Vertex initiates phase 2/3 trial (NCT07204275) of povetacicept in primary membranous nephropathy; recruiting status as of 2026-10-30.
- Oct 30Trial initiationClinicalTrials.gov
Vertex updates Phase 1 trial NCT07868926 (VX-407 ADME study) to recruiting status.
- Oct 29Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07501702) of povetacicept in generalized myasthenia gravis updated to active, not recruiting.
- Oct 28OtherClinicalTrials.gov
Vertex updates ClinicalTrials.gov NCT07538570 phase 4 pain treatment post-knee arthroplasty trial status to ACTIVE_NOT_RECRUITING.
- Oct 27OtherClinicalTrials.gov
Phase 3 trial NCT05331183 for ELX/TEZ/IVA long-term safety/efficacy in non-F508del subjects updated to ACTIVE_NOT_RECRUITING.
- Oct 27Trial initiationClinicalTrials.gov
Phase 1 relative bioavailability study (NCT07813039) of VX-581 tablet formulation status updated to active, not recruiting.
Not financial advice — research and opinion only. Disclosures